01/07/2021 – AB Science announces today the results of the Combined General Shareholders’ Meeting of June 30, 2021 Download PDF Post navigationPreviousPrevious post:Signature of an agreement with historical shareholders to implement a joint strategy to increase the value of masitinibNextNext post:Audio replay of the June 30 2021 Combined Shareholders’ MeetingRelated PostsAB Science announces dosing of first patient in Phase 2 trial of masitinib’s antiviral activity against the SARS-CoV-2 (COVID-19) virus29 November 2021AB Science received FDA authorization to initiate Phase 1/II trial of AB8939 in the treatment of acute myeloid leukemia22 November 2021AB Science received authorization from the FDA to resume patient enrollment in the confirmatory Phase 3 study of masitinib (AB19001) in patients with ALS18 November 2021AB Science granted authorization from the French Health Authority (ANSM) to initiate a study of AB8939 in the treatment of Acute Myeloid Leukemia (AML)18 October 2021AB Science receives FDA authorization to start clinical development program of masitinib in mast cell activation syndrome (MCAS)4 October 2021Revenues for the first half of 2021 and update on AB Science’s activities30 September 2021
AB Science announces dosing of first patient in Phase 2 trial of masitinib’s antiviral activity against the SARS-CoV-2 (COVID-19) virus29 November 2021
AB Science received FDA authorization to initiate Phase 1/II trial of AB8939 in the treatment of acute myeloid leukemia22 November 2021
AB Science received authorization from the FDA to resume patient enrollment in the confirmatory Phase 3 study of masitinib (AB19001) in patients with ALS18 November 2021
AB Science granted authorization from the French Health Authority (ANSM) to initiate a study of AB8939 in the treatment of Acute Myeloid Leukemia (AML)18 October 2021
AB Science receives FDA authorization to start clinical development program of masitinib in mast cell activation syndrome (MCAS)4 October 2021
